In this video, Stephen M. Ansell, MD, PhD professor of medicine, chair of the division of hematology, co-leader of the hematological malignancies program, and interim chair of the department of ...
F. Hoffmann-La Roche Ltd (Roche) has a rich history of antibody therapies to treat cancers (malignancies) that affect B cells (a type of white blood cell), including non-Hodgkin lymphoma and ...
SELLAS Life Sciences Group (NASDAQ:SLS) announced on Thursday promising mid-stage trial results for SLS009, a highly ...
China's National Medical Products Administration has approved a Phase III trial of InnoCare Pharma’s ICP-248 (Mesutoclax) ...
Among adults with relapsed or refractory indolent B-cell non-Hodgkin lymphoma, the phase 2 TRANSCEND FL trial met its primary ...
Despite research showing the benefits of circulating tumor DNA as an indicator of disease remission in B-cell lymphoma ... is the first step toward a cure in treating aggressive B-cell lymphomas ...
Others are faster growing ('aggressive'), for example, diffuse large B-cell lymphoma, Burkitt’s lymphoma ... for these patients (around 60% will be cured), still approximately 30—40% of ...
The treatment will be available in the third line setting for all adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and primary mediastinal large B-cell lymphoma ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback